rethinkPeptides Search
Menu
Home / Research library
Study breakdown

Incretin-based therapies from single to triple agonists offer increasingly effective MASLD/MASH treatment

RPEP-137752025Targher, Giovanni; Mantovani, Alessandro; Byrne, Christopher D; Tilg, Herbert
evidence
The takeaway

Review of single (GLP-1RA), dual (GIP/GLP-1, GLP-1/glucagon), and triple (GIP/GLP-1/glucagon) incretin agonists for MASLD/MASH shows escalating efficacy with increasing receptor targeting, supported by phase 2 trials with histological improvements.

Escalating efficacy: single → dual → triple

Incretin-based liver therapies show increasing MASH efficacy as more receptor targets are engaged—from GLP-1 alone through dual to triple agonists

What the researchers found

GLP-1RA (semaglutide): phase 3 for MASH. Dual agonists (tirzepatide, survodutide): phase 2 histological improvements. Triple agonist (retatrutide): most efficacy data emerging. Escalating efficacy with more receptor targets. Hepatoprotective beyond weight loss.

Why it matters

MASLD/MASH has had no approved pharmacotherapy until recently. Incretin-based drugs offer the first effective treatment class, with escalating potency as more receptor targets are engaged.

How the study worked

Narrative review of clinical trial evidence for single, dual, and triple incretin agonists in MASLD/MASH.

What this study cannot tell us

Most evidence from phase 2 trials. Long-term liver outcome data limited. Optimal receptor combination unclear. Not all patients respond equally.

How to read the evidence

Narrative review of phase 2/3 clinical trial evidence. Growing but not yet definitive evidence base.

When this study was published

Published in 2025.

The bigger picture

The MASLD treatment paradigm is shifting from "no drugs available" to "which combination of incretin receptors to target." This progression from single to triple agonism may define the next decade of liver disease treatment.

Questions still open

  • Will triple agonists prove more effective than dual for MASH?
  • Is the glucagon component essential for liver fat reduction?
  • Should incretin drugs be combined with resmetirom for comprehensive MASH treatment?

Common questions

Are there drugs for fatty liver disease?
Yes, and they are improving rapidly. GLP-1 drugs like semaglutide are in advanced clinical trials for MASH (advanced fatty liver). Newer drugs targeting 2 or 3 incretin receptors simultaneously (tirzepatide, survodutide, retatrutide) show even greater liver improvement in early trials.
Why do more receptor targets help?
Different incretin receptors address different aspects of liver disease: GLP-1 reduces appetite and inflammation, GIP improves fat handling, and glucagon increases energy expenditure and directly clears liver fat. Combining these effects produces increasingly powerful liver improvement.

Read the original research

Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists.

Gut, 74(3), 487-497

View on PubMed ↗Publisher’s paper ↗

Citation

Targher, Giovanni; Mantovani, Alessandro; Byrne, Christopher D; Tilg, Herbert. (2025). Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists.. Gut, 74(3), 487-497. https://doi.org/10.1136/gutjnl-2024-334023